UnitedHealth shares edge lower with RSI approaching buy territory: weekly forecast

Traders Union
All News
Financial News
UnitedHealth slips 0.49% this week

All news

Editors' Picks

Crypto News

Financial News

Market Voices

Billionaires

Companies

Broker News

Regulators News

Jainam Mehta

06.05.2026

UnitedHealth shares edge lower with RSI approaching buy territory: weekly forecast — UnitedHealth slips 0.49% this week

UnitedHealth Group (UNH) is currently trading at $367.88, having slipped $0.64 (0.49%) over the past week and positioning itself in the middle of the weekly range. The asset remains well above its weekly MA-20 ($311.83) and MA-50 ($315.38), indicating ongoing medium-term bullish momentum, but it continues to trade meaningfully below the long-term MA-200 ($463.49), reflecting longer-term seller pressure.

UNH price prediction

24H 4.6%

$415.06

48H 4.87%

$416.13

7D 4.2%

$413.46

1M 5.33%

$417.96

3M -18.04%

$325.22

6M 15.14%

$456.88

12M 27.12%

$504.42

Detailed

Current price: $ 396.8 20.25 5.38%

Real-time Data 15:10

Daily range 394.32

401.20

Weekly range 374.72

386.35

Highlights

UnitedHealth trades with medium-term bullish momentum but remains under longer-term selling pressure below its key 200-day level.
Mixed momentum and oscillator signals reflect overbought conditions, weak directional conviction, and near-term consolidation following a recent pullback.
UNH is likely to stay range-bound between $359 and $376, with greater probability of downside unless a breakout above $376 occurs.

Profit and margin gains drive sentiment amid governance scrutiny this week

UnitedHealth reported strong first-quarter 2026 financials, with revenue rising 2% to $111.7 billion and adjusted EPS reaching $6.90, both beating expectations. The medical loss ratio improved to 83.9% from 84.8% year-on-year, boosting profit margins, while operating cash flow was solid at $8.9 billion. UnitedHealth also announced it will remove prior authorization requirements for 30% of healthcare services that previously needed insurer approval by the end of 2026, aiming to streamline provider and patient experience. The board faced a shareholder proposal for an independent chair, highlighting ongoing governance considerations.

Mixed bullish technicals as momentum wanes below key long-term resistance

Weekly technicals show UNH well above the MA-20 and MA-50, underlining medium-term strength, but still clearly below long-term resistance at the MA-200. Support is established near $315, with dynamic resistance at $376. RSI on the weekly chart nudges toward buy territory; however, Stochastic RSI and CCI both reflect overbought conditions, and Bull/Bear Power echoes ongoing buyer dominance. The MACD and ADX are neutral, signalizing subdued directional conviction, while the Awesome Oscillator supports the bullish tone but with mixed signals overall.

Consolidation expected as downside risk outweighs limited breakout potential

For the next five trading days, UNH is likely to consolidate in a broad range between $359 and $376, tracking its recent weekly volatility. With only one bullish reading among the four main W1 indicators, the probability of a breakout to the upside is moderate at best, and a downward scenario remains more probable. A push above $376 could open the path to $380, while a breakdown below $359 would expose UNH to the risk of further declines toward lower weekly support levels.

Earlier, analysts noted that UnitedHealth's near-term technical momentum was strong, but that persistent long-term resistance and overbought signals called for caution. The latest developments reinforce this cautious tone, as medium-term momentum remains constructive but overextended technicals and muted directional conviction suggest traders should closely monitor $359 as a critical support level for early signs of potential downside.

Source of Data: UNH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.